• Opioids: The rise and fall of the Sackler family

    "No one has impacted the very nature of medical marketing more than the multi-talented Dr. Arthur Sackler," says the Medical Advertising Hall of Fame about the man whose family name is now synonymous with the opioid epidemic.

  • Particle therapy: High precision technology against cancer

    Particle therapy fights with a prescribed high load and extreme precision against radioresistant tumors, while preserving healthy tissue.

  • 2031: Artificial Intelligence conquers healthcare

    2031. Catherine has a chronic illness. AI and digital interventions shape her care through diagnosis, psychological support, therapeutic guidance, and medication.

  • Hello Doc! I am also a physician

    When physicians present to a colleague as a patient, should they disclose their profession? Are there subjective preferences, or an ethical duty to do so?

  • Air pollution in the Asia-Pacific region: Increase in respiratory diseases

    APAAACI´s recent white paper showed that various air pollutants threaten human respiratory and cardiovascular health

  • COVID-19 in the Asia-Pacific region: Rise of allergies and contact dermatitis

    The APAAACI Task Force on COVID-19 recognized most common atopic conditions and skin allergies in healthcare workers during the pandemic.

  • Being a young physician during the pandemic – a hard lesson to learn

    Young physicians in Brazil and Ireland are struggling with anxiety disorder even months after working in clinical practice during the pandemic.

  • COVID-19: Risks associated with unvaccinated pregnant women

    During pregnancy, women are not only at high risk for severe progression of the disease, they also face an increased risk of premature births and stillbirths.

  • Development of the cancer protein Ki-67 is discovered in Leipzig, Germany

    In pathology, the protein Ki-67 is used to analyse conspicuous tissue changes. Researchers have discovered how this helpful protein is formed.

  • New study looks into causal link between Epstein-Barr virus and Multiple Sclerosis

    Compelling evidence suggests that many MS cases could be prevented by stopping EBV infection.

  • Second shot COVID-19 vaccine urgently needed for patients treated with immunomodulators

    In 17% of patients with immune-mediated inflammatory diseases (IMID) on immunomodulating treatment, no seroconversion occurred after their first dose of SARS-CoV-2 vaccination.

  • Marked elevation of SII index in psoriasis patients with cardiovascular comorbidity

    The systemic immune-inflammation (SII) index emerged as a novel biomarker associated with a worse prognosis in different diseases.

  • COVID-19 and psoriasis: patients benefit from TNF blockers

    Non-biologic systemic treatment more than doubled the risk for hospitalisation and death compared with tumour necrosis factor (TNF) inhibition.

  • Inhibition of heat shock protein: A novel way to treat psoriasis?

    Inhibition of heat shock protein 90 (HSP90) may be an interesting novel treatment mode for psoriasis. In a proof-of-concept trial, therapy with RGRN-305 showed marked efficacy with an acceptable safety profile.

  • PsA: Upregulation of genes related to neutrophils and monocytes

    Gene profiles for active psoriatic arthritis patients compared with healthy controls showed that genes related to neutrophils, monocytes, eosinophils, and macrophages are upregulated.

  • Guselkumab shows highest drug survival among systemic treatments

    In a comparison of 5 commonly used systemic treatments for psoriasis, guselkumab demonstrated the highest drug survival and adalimumab the lowest at 1 and 2 years.

  • Distinct differences in the microbiota of psoriasis patients

    Psoriasis patients' microbiota are less diverse and have a decreased functional richness compared to healthy controls. Differences occured also in similar lifestyles of psoriasis patients and partners.

  • Tapering biologics: Anti-drug antibodies are not common

    Most healthcare professionals perform dose reductions in psoriasis treatments. A main concern for professionals who do not taper biologics is the formation of anti-drug antibodies.

  • HLA-positive patients treated with ustekinumab show a better drug survival

    A real-world analysis from the BADBIR registry showed that drug survival of ustekinumab, but not from other biologics due to effectiveness, is associated with the psoriasis risk allele HLA-C*06:02.

  • Psoriasis is associated with a higher cancer risk

    A large registry study showed that psoriasis is linked with a higher cancer risk overall and in specific sites, particularly in severe disease. Psoriasis was associated with several cancers beyond those currently regarded as connected.

  • 11 |
  • 12 |
  • 13 |
  • 14 |
  • 15 |
  • 16 |
  • 17 |
  • 18 |
  • 19 |
  • 20 |
  • 21 |